|
1
|
Bedikian AY: Metastatic uveal melanoma
therapy: Current options. Int Ophthalmol Clin. 46:151–166. 2006.
View Article : Google Scholar
|
|
2
|
Biswas J, Krishnakumar S and Shanmugam MP:
Uveal melanoma in Asian Indians: A clinicopathological study. Arch
Ophthalmol. 120:522–523. 2002.PubMed/NCBI
|
|
3
|
Sakamoto T, Sakamoto M, Yoshikawa H, Hata
Y, Ishibashi T, Ohnishi Y and Inomata H: Histologic findings and
prognosis of uveal malignant melanoma in Japanese patients. Am J
Ophthalmol. 121:276–283. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kuo PK, Puliafito CA, Wang KM, Liu HS and
Wu BF: Uveal melanoma in China. Int Ophthalmol Clin. 22:57–71.
1982. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Singh AD, Turell ME and Topham AK: Uveal
melanoma: Trends in incidence, treatment, and survival.
Ophthalmology. 118:1881–1885. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Collaborative Ocular Melanoma Study Group:
Assessment of metastatic disease status at death in 435 patients
with large choroidal melanoma in the Collaborative Ocular Melanoma
Study (COMS): COMS report no. 15. Arch Ophthalmol. 119:670–676.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gragoudas ES, Egan KM, Seddon JM, Glynn
RJ, Walsh SM, Finn SM, Munzenrider JE and Spar MD: Survival of
patients with metastases from uveal melanoma. Ophthalmology.
98:383–390. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
O’Hayre M, Vázquez-Prado J, Kufareva I,
Stawiski EW, Handel TM, Seshagiri S and Gutkind JS: The emerging
mutational landscape of G proteins and G-protein-coupled receptors
in cancer. Nat Rev Cancer. 13:412–424. 2013. View Article : Google Scholar
|
|
9
|
Daniels AB, Lee JE, MacConaill LE,
Palescandolo E, Van Hummelen P, Adams SM, DeAngelis MM, Hahn WC,
Gragoudas ES, Harbour JW, et al: High throughput mass
spectrometry-based mutation profiling of primary uveal melanoma.
Invest Ophthalmol Vis Sci. 53:6991–6996. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ambrosini G, Pratilas CA, Qin LX, Tadi M,
Surriga O, Carvajal RD and Schwartz GK: Identification of unique
MEK-dependent genes in GNAQ mutant uveal melanoma involved in cell
growth, tumor cell invasion, and MEK resistance. Clin Cancer Res.
18:3552–3561. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Van Raamsdonk CD, Griewank KG, Crosby MB,
Garrido MC, Vemula S, Wiesner T, Obenauf AC, Wackernagel W, Green
G, Bouvier N, et al: Mutations in GNA11 in uveal melanoma. N Engl J
Med. 363:2191–2199. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mumm JS and Kopan R: Notch signaling: From
the outside in. Dev Biol. 228:151–165. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Brou C, Logeat F, Gupta N, Bessia C,
LeBail O, Doedens JR, Cumano A, Roux P, Black RA and Israël A: A
novel proteolytic cleavage involved in Notch signaling: The role of
the disintegrin-metalloprotease TACE. Mol Cell. 5:207–216. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Borggrefe T and Oswald F: The Notch
signaling pathway: Transcriptional regulation at Notch target
genes. Cell Mol Life Sci. 66:1631–1646. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jarriault S, Le Bail O, Hirsinger E,
Pourquié O, Logeat F, Strong CF, Brou C, Seidah NG and Isral A:
Delta-1 activation of notch-1 signaling results in HES-1
transactivation. Mol Cell Biol. 18:7423–7431. 1998.PubMed/NCBI
|
|
16
|
Liu ZJ, Xiao M, Balint K, Smalley KS,
Brafford P, Qiu R, Pinnix CC, Li X and Herlyn M: Notch1 signaling
promotes primary melanoma progression by activating
mitogen-activated protein kinase/phosphatidylinositol 3-kinase-Akt
pathways and up-regulating N-cadherin expression. Cancer Res.
66:4182–4190. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Pinnix CC, Lee JT, Liu ZJ, McDaid R,
Balint K, Beverly LJ, Brafford PA, Xiao M, Himes B, Zabierowski SE,
et al: Active Notch1 confers a transformed phenotype to primary
human melanocytes. Cancer Res. 69:5312–5320. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Asnaghi L, Ebrahimi KB, Schreck KC, Bar
EE, Coonfield ML, Bell WR, Handa J, Merbs SL, Harbour JW and
Eberhart CG: Notch signaling promotes growth and invasion in uveal
melanoma. Clin Cancer Res. 18:654–665. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Babchia N, Calipel A, Mouriaux F, Faussat
AM and Mascarelli F: The PI3K/Akt and mTOR/P70S6K signaling
pathways in human uveal melanoma cells: Interaction with B-Raf/ERK.
Invest Ophthalmol Vis Sci. 51:421–429. 2010. View Article : Google Scholar
|
|
20
|
Mende U, Kagen A, Cohen A, Aramburu J,
Schoen FJ and Neer EJ: Transient cardiac expression of
constitutively active Gαq leads to hypertrophy and
dilated cardiomyopathy by calci-neurin-dependent and independent
pathways. Proc Natl Acad Sci USA. 95:13893–13898. 1998. View Article : Google Scholar
|
|
21
|
Marinissen MJ, Servitja JM, Offermanns S,
Simon MI and Gutkind JS: Thrombin protease-activated receptor-1
signals through Gq- and G13-initiated MAPK
cascades regulating c-Jun expression to induce cell transformation.
J Biol Chem. 278:46814–46825. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yu FX, Luo J, Mo JS, Liu G, Kim YC, Meng
Z, Zhao L, Peyman G, Ouyang H, Jiang W, et al: Mutant Gq/11 promote
uveal melanoma tumorigenesis by activating YAP. Cancer Cell.
25:822–830. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cheng P, Kumar V, Liu H, Youn JI, Fishman
M, Sherman S and Gabrilovich D: Effects of notch signaling on
regulation of myeloid cell differentiation in cancer. Cancer Res.
74:141–152. 2014. View Article : Google Scholar
|
|
24
|
Neradugomma NK, Subramaniam D, Tawfik OW,
Goffin V, Kumar TR, Jensen RA and Anant S: Prolactin signaling
enhances colon cancer stemness by modulating Notch signaling in a
Jak2-STAT3/ERK manner. Carcinogenesis. 35:795–806. 2014. View Article : Google Scholar :
|
|
25
|
Xie M, He CS, Wei SH and Zhang L: Notch-1
contributes to epidermal growth factor receptor tyrosine kinase
inhibitor acquired resistance in non-small cell lung cancer in
vitro and in vivo. Eur J Cancer. 49:3559–3572. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lamba S, Felicioni L, Buttitta F, Bleeker
FE, Malatesta S, Corbo V, Scarpa A, Rodolfo M, Knowles M, Frattini
M, et al: Mutational profile of GNAQQ209 in human
tumors. PLoS One. 4:e68332009. View Article : Google Scholar
|
|
27
|
Tschaharganeh DF, Chen X, Latzko P, Malz
M, Gaida MM, Felix K, Ladu S, Singer S, Pinna F, Gretz N, et al:
Yes-associated protein up-regulates Jagged-1 and activates the
Notch pathway in human hepatocellular carcinoma. Gastroenterology.
144:1530–1542.e12. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kan Z, Jaiswal BS, Stinson J, Janakiraman
V, Bhatt D, Stern HM, Yue P, Haverty PM, Bourgon R, Zheng J, et al:
Diverse somatic mutation patterns and pathway alterations in human
cancers. Nature. 466:869–873. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Prickett TD, Wei X, Cardenas-Navia I, Teer
JK, Lin JC, Walia V, Gartner J, Jiang J, Cherukuri PF, Molinolo A,
et al: Exon capture analysis of G protein-coupled receptors
identifies activating mutations in GRM3 in melanoma. Nat Genet.
43:1119–1126. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
30
|
Küsters-Vandevelde HV, Klaasen A, Küsters
B, Groenen PJ, van Engen-van Grunsven IA, van Dijk MR, Reifenberger
G, Wesseling P and Blokx WA: Activating mutations of the GNAQ gene:
A frequent event in primary melanocytic neoplasms of the central
nervous system. Acta Neuropathol. 119:317–323. 2010. View Article : Google Scholar :
|
|
31
|
Van Raamsdonk CD, Bezrookove V, Green G,
Bauer J, Gaugler L, O’Brien JM, Simpson EM, Barsh GS and Bastian
BC: Frequent somatic mutations of GNAQ in uveal melanoma and blue
naevi. Nature. 457:599–602. 2009. View Article : Google Scholar :
|
|
32
|
Vallar L, Spada A and Giannattasio G:
Altered Gs and adenylate cyclase activity in human
GH-secreting pituitary adenomas. Nature. 330:566–568. 1987.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lyons J, Landis CA, Harsh G, Vallar L,
Grünewald K, Feichtinger H, Duh QY, Clark OH, Kawasaki E, Bourne
HR, et al: Two G protein oncogenes in human endocrine tumors.
Science. 249:655–659. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Van Raamsdonk CD, Fitch KR, Fuchs H, de
Angelis MH and Barsh GS: Effects of G-protein mutations on skin
color. Nat Genet. 36:961–968. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
35
|
Markby DW, Onrust R and Bourne HR:
Separate GTP binding and GTPase activating domains of a G alpha
subunit. Science. 262:1895–1901. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
McCubrey JA, Steelman LS, Chappell WH,
Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M,
Tafuri A, et al: Roles of the Raf/MEK/ERK pathway in cell growth,
malignant transformation and drug resistance. Biochim Biophys Acta.
1773:1263–1284. 2007. View Article : Google Scholar
|
|
37
|
Hoek K, Rimm DL, Williams KR, Zhao H,
Ariyan S, Lin A, Kluger HM, Berger AJ, Cheng E, Trombetta ES, et
al: Expression profiling reveals novel pathways in the
transformation of melanocytes to melanomas. Cancer Res.
64:5270–5282. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Qin JZ, Stennett L, Bacon P, Bodner B,
Hendrix MJ, Seftor RE, Seftor EA, Margaryan NV, Pollock PM, Curtis
A, et al: p53-independent NOXA induction overcomes apoptotic
resistance of malignant melanomas. Mol Cancer Ther. 3:895–902.
2004.PubMed/NCBI
|
|
39
|
Asnaghi L, Handa JT, Merbs SL, Harbour JW
and Eberhart CG: A role for Jag2 in promoting uveal melanoma
dissemination and growth. Invest Ophthalmol Vis Sci. 54:295–306.
2013. View Article : Google Scholar
|
|
40
|
Huang X, Wang L, Zhang H, Wang H, Zhao X,
Qian G, Hu J, Ge S and Fan X: Therapeutic efficacy by targeting
correction of Notch1-induced aberrants in uveal tumors. PLoS One.
7:e443012012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zhou D, Zhang Y, Wu H, Barry E, Yin Y,
Lawrence E, Dawson D, Willis JE, Markowitz SD, Camargo FD, et al:
Mst1 and Mst2 protein kinases restrain intestinal stem cell
proliferation and colonic tumorigenesis by inhibition of
Yes-associated protein (Yap) overabundance. Proc Natl Acad Sci USA.
108:E1312–E1320. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Feng X, Degese MS, Iglesias-Bartolome R,
Vaque JP, Molinolo AA, Rodrigues M, Zaidi MR, Ksander BR, Merlino
G, Sodhi A, et al: Hippo-independent activation of YAP by the GNAQ
uveal melanoma oncogene through a trio-regulated rho GTPase
signaling circuitry. Cancer Cell. 25:831–845. 2014. View Article : Google Scholar : PubMed/NCBI
|
